How acute promyelocytic leukaemia revived arsenic
- 1 September 2002
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 2 (9) , 705-714
- https://doi.org/10.1038/nrc887
Abstract
Despite its many therapeutic qualities, arsenic trioxide has been more commonly remembered as Madame Bovary's poison than as an anticancer drug. The ability of arsenic trioxide to treat acute promyelocytic leukaemia has radically changed this view, providing new insights into the pathogenesis of this malignancy and raising hopes that arsenicals might be useful in treating other cancers.Keywords
This publication has 102 references indexed in Scilit:
- Lineage restriction of the RARalpha gene expression in myeloid differentiationBlood, 2001
- Regulation of Pax3 transcriptional activity by SUMO-1-modified PMLOncogene, 2001
- Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic TrioxideNew England Journal of Medicine, 1998
- Arsenic and Mercury in Traditional Chinese Herbal BallsNew England Journal of Medicine, 1995
- Did Napoleon die from arsenical poisoning?The Lancet, 1994
- Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cellsCell, 1994
- The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RARCell, 1991
- Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PMLCell, 1991
- The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locusNature, 1990
- Molecular Analysis of Acute Promyelocytic Leukemia Breakpoint Cluster Region on Chromosome 17Science, 1990